Hypomethylation of 111 Probes Predicts Poor Prognosis for Glioblastoma

Qi Chen, Min Zhao, Chengliang Yin, Shiyu Feng, Jian Hu, Qiang Zhang, Xiaodong Ma, Wanguo Xue, Jinlong Shi

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Glioblastoma (GBM) is a complicated brain tumor with heterogeneous outcome. Identification of effective biomarkers is an urgent need for the treatment decision-making and precise evaluation of prognosis. Based on a relatively large dataset of genome-wide methylation (138 glioblastoma patients), a joint-score of 111 methyl-probes was found to be of statistical significance for prognostic evaluation. Low joint-score were significantly associated with adverse outcomes (OS: P < 0.001, PFS: P = 0.03). Multivariable analyses adjusted for known risk factors confirmed the low joint-score of 111 methyl-probes as a high risk factor. The prognostic value of the methylated joint-score was further validated in another dataset of glioblastoma patients (OS: P = 0.006). Additionally, variance analysis revealed that aberrant genetic and epigenetic alterations were significantly associated with the joint-score of those methyl-probes. In conclusion, our results supported the joint-score of 111 methyl-probes as a potential prognosticator for the precision treatment of glioblastoma.

Original languageEnglish (US)
Article number1137
JournalFrontiers in Neuroscience
Volume13
DOIs
StatePublished - Oct 25 2019

Keywords

  • biomarker
  • glioblastoma
  • joint-score
  • methylation
  • prognostic evaluation

ASJC Scopus subject areas

  • General Neuroscience

Fingerprint

Dive into the research topics of 'Hypomethylation of 111 Probes Predicts Poor Prognosis for Glioblastoma'. Together they form a unique fingerprint.

Cite this